Hisashi Mitsuguchi

Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.

Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.

Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.